Journal des maladies pulmonaires et du traitement

Pulmonary hypertension is a life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart failure and other complications. Pharmacological agents are the primary mode of treatment for pulmonary hypertension, and new agents are continuously being developed and studied to improve patient outcomes. In this assessment, we review the current literature and analyze clinical trials to evaluate the efficacy of new pharmacological agents in the treatment of pulmonary hypertension. We discuss the potential benefits and limitations of these new agents and provide clinicians and patients with a better understanding of the available treatment options.

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory infection that primarily affects infants and young children, although it can also impact adults, especially those with weakened immune systems. The virus spreads through close contact with an infected person and the symptoms range from mild to severe, including cough, runny nose, fever and wheezing. RSV is a significant cause of respiratory illness worldwide, leading to hospitalizations and even deaths in severe cases. Understanding the transmission, risk factors, symptoms, diagnosis and treatment of RSV is crucial for preventing and managing the spread of this infection.